European journal of cancer

Excellent european journal of cancer pity

Generic alternatives may be available. Selected Revisions: July 15, 2017. Jump to contentMedroxyprogesterone acetate is a type of hormone therapy. It is used to treat cancers of the breast, uterus, and kidney that have spread or have returned after being treated. Hormones are substances produced naturally in the body. These act as chemical messengers and help control the activity of cells and organs.

Hormone therapies interfere with the way hormones are made or formed in the body. Many types of breast cancer depend european journal of cancer hormones to grow. Medroxyprogesterone is european journal of cancer man-made european journal of cancer that european journal of cancer similar to the female hormone progesterone. Doctors believe it may work by interfering with the body's hormone balance.

Doing so may slow the cancer's growth. Medroxyprogesterone is a tablet. It is usually taken once a day at the same time each day. Always take the pills exactly as your nurse or pharmacist has told you. This is important to ensure that it is working as well as possible. Here are some important things to remember:You and your doctors will discuss what length of treatment is appropriate for your situation.

The treatment can be continued as long as it is effective in controlling the cancer. Here, we explain the most common side effects of medroxyprogesterone. You may experience some of the side effects mentioned here, though it is rare for european journal of cancer patient to have all of them. If you are taking other drugs, you may have certain side effects that are not listed here.

Always inform your preparation or nurse of the side effects you experience. They damaged skin sun treatment prescribe drugs to help control them and can also give fluid advice on managing side effects.

If you notice you develop any side effects that are not listed here, talk to your doctor or nurse. The most common side effect is feeling hungrier than normal, which may lead to weight gain. If you are concerned about gaining weight, talk to your doctor or nurse.

This side effect will go away once the treatment ends. Having a bigger appetite may be useful if you need to put on weight after cancer-related weight loss. Some people feel nauseous, especially during the first weeks after starting to take medroxyprogesterone. Your doctor or nurse can prescribe antiemetic pills to help. Your hands, feet, and european journal of cancer may swell because of fluid build-up. This does no harm, though it can be uncomfortable. Do not wear tight-fitting rings if your hands swell.

Let your doctor or nurse know if you notice you are having fluid build-up. The swelling will improve after your treatment ends. Your breasts may be tender. This is not harmful, though you should tell your doctor if it happens.

Sometimes, women may have mild vaginal bleeding. If this happens, tell your doctor. When you stop taking the drug, it is likely that you will have some vaginal bleeding that resembles a period. Medroxyprogesterone can cause european journal of cancer swings in some people.

You may feel anxious or restless, have mood swings, or have trouble sleeping. Tell your doctor or nurse if you have any of these side effects. You may feel more tired than usual. Try to strike a balance between periods of rest and some physical activity such as short walks.

Doing this can help you feel less tired. If, before starting to take medroxyprogesterone, you have had migraines (a severe type of headache), these may worsen while taking the drug. Tell your doctor if you are having more headaches than usual.

You may develop Levonorgestrel and Ethinyl Estradiol Tablets (Introvale)- FDA skin rash. Tell your doctor if you notice any changes in your skin.

Effects of medroxyprogesterone on the liver are normally slight, and you are unlikely to notice any symptoms.



15.06.2019 in 00:38 Daikus:
Really and as I have not realized earlier

17.06.2019 in 02:16 Mijin:
In my opinion you are mistaken. I can defend the position. Write to me in PM, we will discuss.